Cancer's Achilles' heel

December 2007
Marketing Health Services;Winter2007, Vol. 27 Issue 4, p9
Academic Journal
The article reports that patients with advanced melanoma who participated in early tests of an experimental drug seemed to show signs of a slowdown in the spreading of the deadly skin cancer. According to Synta Pharmaceuticals Corp., test patients who received the drug survived an average of 3.7 months without new cancer lesions, compared with 1.8 months for those who got the standard treatment. The treatment is given in pill form, but the development of the drug is in such an early stage, it has yet to be named. It must undergo more rigorous testing before the company will seek approval in the United States.


Related Articles

  • VIRTUALLY 100 PERCENT CANCER CURE.  // Prevention;Oct89, Vol. 41 Issue 10, p14 

    Reports on the findings of University of Pennsylvania researchers that there is nearly 100 percent chance of curing melanoma, the most dangerous skin cancer. Importance of early detection in increasing the chance of cure; Cure rate in the radial growth phase.

  • Israeli-American Team Unveils Revolutionary Drug in Fight Against Skin Cancer.  // Israel Faxx;6/9/2014, Vol. 22 Issue 117W, p5 

    The article offers information on the new biological treatment found by Israeli and American researchers for curing the skin cancer and for the treatment of melanoma.

  • Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis. Jiang, Guan; Li, Rong-Hua; Sun, Chao; Liu, Yan-Qun; Zheng, Jun-Nian // PLoS ONE;Dec2014, Vol. 9 Issue 12, p1 

    Background: Malignant melanoma is the most aggressive and deadly form of skin cancer. Dacarbazine (DTIC) has been the approved first-line treatment for metastatic melanoma in routine clinical practice. However, response rates with single-agent DTIC are low. The objective of this study was to...

  • Superhero T Cells. JM; Harrar, Sari // Prevention;Mar2003, Vol. 55 Issue 3, p179 

    Doctors may soon have another weapon against melanoma, the skin cancer that kills thousands of Americans each year. An experimental technique, called adoptive transfer, begins by taking "killer" T cells from a melanoma patient's own immune system and exposing them to a fragment of the cancer, so...

  • "Every Day I'm Alive, It's a MIRACLE" Griffin, Katherine // Good Housekeeping;Apr2011, Vol. 252 Issue 4, p59 

    The article examines a drug called tremelimumab, which has allegedly proven successful in treating the cancer melanoma. The author provides the story of Maggie Barbieri, a middle school teacher and mother who was diagnosed with melanoma that had metastasized to her liver. Barbieri was treated...

  • High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Faje, Alexander T.; Lawrence, Donald; Flaherty, Keith; Freedman, Christine; Fadden, Riley; Rubin, Krista; Cohen, Justine; Sullivan, Ryan J. // Cancer (0008543X);Sep2018, Vol. 124 Issue 18, p3706 

    Background: It remains unclear whether high doses of glucocorticoids have a negative impact on the efficacy of checkpoint inhibitors. To control for the potential association between immune-related adverse events (irAEs) and improved survival, this study examined a unique cohort of...

  • Breakthrough reduces skin cancer recurrence.  // Total Health;Aug94, Vol. 16 Issue 4, p14 

    Reports on researchers at Thomas Jefferson University in Philadelphia's development of a vaccine that will reduce the recurrence of skin cancer, melanoma.

  • BRAF V600E MUTATIONS IN METASTATIC MELANOMA - CASE REPORT. Inić, Ivana; Inić, Momcilo; Inić, Zorka; Zegarac, Milan; Martinović, Aleksandar; Šašić, Miomir; Bracanović, Miloš; Pupić, Gordana // Acta Medica Medianae;Sep2014, Vol. 53 Issue 3, p39 

    The treatment of metastatic melanoma represents a challenge. Vemurafenib, a selective BRAF kinase inhibitor, is a new medicine against carcinoma. Recently, it has been shown that it raises the survival rate among patients with metastatic melanoma who have BRAF V600 mutation. This work will...

  • New Effective Treatments for Non-Caucasians. Gorgos, Diana // Dermatology Nursing;Aug2003, Vol. 15 Issue 4, p369 

    Reports on new effective and safe treatments for a variety of pigmentation disorders that affect patients of color in the U.S., as of August 2003. Melasma; Pseudofolliculitis barbae; Vitiligo; Skin cancer and melanoma.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics